Related Experiment Video

Updated: Sep 27, 2026

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction
03:42

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction

Published on: March 29, 2024

Undertreatment of hyperlipidemia in patients with coronary artery disease and heart failure

Carla A Sueta1, Mark W Massing, Mridul Chowdhury

  • 1Medical Review of North Carolina, Cary, North Carolina 27511, USA.

Journal of Cardiac Failure
|March 4, 2003
PubMed

Insights

Patients with coronary artery disease and heart failure (CAD+HF) receive less lipid testing and fewer lipid-lowering treatments than those with CAD alone, despite high cardiovascular risk. Increased testing and treatment are needed for this high-risk group.

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Patients with coronary artery disease and heart failure (CAD+HF) face elevated risks of cardiovascular events.
  • This study compares lipid assessment and treatment rates in CAD+HF patients versus those with CAD alone.

Purpose of the Study:

  • To evaluate the frequency of lipid assessment and the prescription of lipid-lowering agents in outpatients with combined CAD+HF.
  • To identify disparities in lipid management between CAD+HF patients and CAD-only patients.

Main Methods:

  • Analysis of a national retrospective chart audit of 41,487 coronary artery disease patients.
  • Categorization of patients into CAD+HF (34%) and CAD alone groups.
  • Comparison of lipid assessment documentation and lipid-lowering drug prescription rates.

Main Results:

  • Low-density lipoprotein (LDL) cholesterol documentation was lower in CAD+HF patients (53%) compared to CAD-only patients (69%).
  • Lipid-lowering drugs were prescribed less frequently in CAD+HF patients (36%) versus CAD-only patients (52%).
  • Documented LDL levels significantly increased the likelihood of receiving lipid-lowering medication.

Conclusions:

  • Patients with CAD, heart failure (HF), and advanced age represent a high-risk group with suboptimal lipid-lowering treatment rates.
  • There is a critical need for enhanced LDL cholesterol testing and more aggressive lipid-lowering treatment strategies in patients with concurrent CAD and HF.
Abstract

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...